OnKure Therapeutics (NASDAQ:OKUR) Announces Earnings Results, Beats Estimates By $0.05 EPS

OnKure Therapeutics (NASDAQ:OKUR) announced its earnings results on Wednesday. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.05, FiscalAI reports.

OnKure Therapeutics Trading Up 3.6%

OKUR stock traded up $0.09 during trading on Wednesday, reaching $2.59. 876,952 shares of the stock were exchanged, compared to its average volume of 269,594. OnKure Therapeutics has a twelve month low of $2.01 and a twelve month high of $5.38. The company has a market capitalization of $104.64 million, a P/E ratio of -0.74 and a beta of 0.18. The stock has a 50 day simple moving average of $2.85 and a 200-day simple moving average of $3.59.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on OKUR. Weiss Ratings raised shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. HC Wainwright lowered their price target on OnKure Therapeutics to $21.00 and set a “buy” rating on the stock in a research report on Monday, July 20th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 price target on shares of OnKure Therapeutics in a research report on Friday, August 14th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $17.50.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target cancer-driving transcription factors and related proteins that are difficult to address with conventional drug approaches.

Its lead product candidate, OKN4395, is an oral small-molecule inhibitor of the EP300/CBP bromodomains. The program is being investigated as a potential treatment for solid tumors, including in combination with immune checkpoint inhibitors such as pembrolizumab.